Literature DB >> 18549874

Executive functioning component mechanisms and schizophrenia.

John G Kerns1, Keith H Nuechterlein, Todd S Braver, Deanna M Barch.   

Abstract

BACKGROUND: Executive functioning refers to a set of processes involved in complex, goal-directed thought and behavior involving multiple brain regions (e.g., prefrontal cortex, parietal cortex, basal ganglia) and multiple neurotransmitters (e.g., dopamine, glutamate, gamma-aminobutyric acid). People with schizophrenia exhibit executive functioning deficits that are associated with treatment-refractory aspects of the disorder. Although there is general consensus about what cognitive tasks involve executive functioning, there is disagreement about the specific cognitive mechanisms that comprise executive functioning.
METHODS: This article discusses a number of possible candidate executive functioning mechanisms and provides a summary of the consensus reached by the executive functioning discussion group at the first CNTRICS (Cognitive Neuroscience for Treatment Research to Improve Cognition in Schizophrenia) meeting in Washington, DC.
RESULTS: The consensus was that two constructs have a well-founded basis in basic cognitive neuroscience research and seem to be impaired in schizophrenia: 1) rule generation and selection; and 2) dynamic adjustments in control (i.e., after conflict and errors).
CONCLUSIONS: The consensus of the first CNTRICS meeting was that immediate translation of measures of these constructs for use in schizophrenia should be pursued. A number of other constructs (e.g., scheduling, sequencing) could also be very important for schizophrenia and are in need of more basic and more clinical research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549874     DOI: 10.1016/j.biopsych.2008.04.027

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  63 in total

1.  Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

Authors:  Kathleen S Alexander; Hui-Qiu Wu; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

2.  Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia.

Authors:  James A Waltz; Julie B Schweitzer; Thomas J Ross; Pradeep K Kurup; Betty J Salmeron; Emma J Rose; James M Gold; Elliot A Stein
Journal:  Neuropsychopharmacology       Date:  2010-08-18       Impact factor: 7.853

3.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Ikwunga Wonodi; Rosalinda C Roberts; Arash Rassoulpour; Robert P McMahon; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-10-29       Impact factor: 9.306

4.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

Review 5.  CNTRICS final task selection: executive control.

Authors:  Deanna M Barch; Todd S Braver; Cameron S Carter; Russell A Poldrack; Trevor W Robbins
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

6.  Impaired Activation in Cognitive Control Regions Predicts Reversal Learning in Schizophrenia.

Authors:  Adam J Culbreth; James M Gold; Roshan Cools; Deanna M Barch
Journal:  Schizophr Bull       Date:  2015-06-06       Impact factor: 9.306

7.  Enhancing Psychosis-Spectrum Nosology Through an International Data Sharing Initiative.

Authors:  Anna R Docherty; Eduardo Fonseca-Pedrero; Martin Debbané; Raymond C K Chan; Richard J Linscott; Katherine G Jonas; David C Cicero; Melissa J Green; Leonard J Simms; Oliver Mason; David Watson; Ulrich Ettinger; Monika Waszczuk; Alexander Rapp; Phillip Grant; Roman Kotov; Colin G DeYoung; Camilo J Ruggero; Nicolas R Eaton; Robert F Krueger; Christopher Patrick; Christopher Hopwood; F Anthony O'Neill; David H Zald; Christopher C Conway; Daniel E Adkins; Irwin D Waldman; Jim van Os; Patrick F Sullivan; John S Anderson; Andrey A Shabalin; Scott R Sponheim; Stephan F Taylor; Rachel G Grazioplene; Silviu A Bacanu; Tim B Bigdeli; Corinna Haenschel; Dolores Malaspina; Diane C Gooding; Kristin Nicodemus; Frauke Schultze-Lutter; Neus Barrantes-Vidal; Christine Mohr; William T Carpenter; Alex S Cohen
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

Review 8.  CNTRICS final task selection: control of attention.

Authors:  Keith H Nuechterlein; Steven J Luck; Cindy Lustig; Martin Sarter
Journal:  Schizophr Bull       Date:  2009-01       Impact factor: 9.306

9.  The impact of motivation on cognitive performance in an animal model of the negative and cognitive symptoms of schizophrenia.

Authors:  Ryan D Ward; Vanessa Winiger; Kerin K Higa; Julia B Kahn; Eric R Kandel; Peter D Balsam; Eleanor H Simpson
Journal:  Behav Neurosci       Date:  2015-04-27       Impact factor: 1.912

10.  Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment.

Authors:  Kathleen S Alexander; Julie M Brooks; Martin Sarter; John P Bruno
Journal:  Neuropsychopharmacology       Date:  2009-08-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.